Stay updated on Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.

Latest updates to the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page
- CheckyesterdayChange DetectedA new revision entry v3.5.4 was added to the history. The previous entry v3.5.3 was removed, updating the page’s revision trail.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedUpdates the ClinicalTrials.gov page revision identifier from v3.5.2 to v3.5.3, reflecting a site/version change rather than a modification to the underlying trial record.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision history shows a new revision v3.5.0 added and an older revision v3.4.3 removed.SummaryDifference0.1%

- Check66 days agoChange DetectedThe revision history shows a new entry for v3.4.3 added and the previous v3.4.2 entry removed.SummaryDifference0.1%

- Check94 days agoChange DetectedAdded Revision: v3.4.2 to the history; removed the funding notice and the earlier Revision: v3.4.1.SummaryDifference1.0%

Stay in the know with updates to Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Role in ASCT in Relapsed Myeloma - Clinical Trial page.